Six Month Glycemic Control With A Hybrid Closed Loop (HCL) System In Type 1 Diabetes Patients in a Latin American Country.

The goal of this study was to assess the 6-months effectiveness of HCL on glycemic control in T1D patients in Latin America. An exploratory analysis of data prospectively collected from non-selected consecutive patients with T1D that initiated treatment with MiniMed™ 670G system in Argentina was conducted. Baseline and follow up visits at days 7, 28, 90 and 180 days were carried out and data was downloaded in each visit. A total of 30 patients were included (age range 9-57), female 63.3%, previous use of SAP-PLGM 73.3% (n=22), baseline HbA1c 7.4 ± 1%. Time in range (TIR) between 70-180 mg/dl significantly increased from 65.1% at baseline to 77.3%, 76.2%, 75.7%, and 75,2% at days 7, 28, 90 and 180 respectively. Time above range (>180 mg/dL) statistically significantly decreased from 33% to 22.5% (p<0.001) while time below range (<70 mg/dL) did not change. Mean glucose levels were reduced from 163.5 at baseline to 150.9 mg/dl (p=0.001) at last visit. The auto mode (AM) feature was used above 90 % of time. Virtual training was successfully completed with a NPS® of 87%. This analysis confirms that the use of MiniMed™ 670G System allow to successfully achieve glycemic control within recommended targets in a non-selected patient population virtually trained in the use of the system in Argentina.